


JUL 25 - SEP 25

ISSUE NO.31



PHARMACY AND POISONS BOARD

NEWSLETTER

www.ppb.go.ke



**Kenya Advances Toward WHO
Maturity Level 3 in Regulatory
Systems**

→ Story Page 5



PHARMACY AND POISONS BOARD

AVOID SELF-MEDICATION!

Taking medicine without medical advice can be dangerous.


Always consult a doctor or pharmacist.

Buy medicines only from PPB-registered outlets.

Verify here:

practice.pharmacyboardkenya.org/Licensestatus?register=facilities

Ensuring quality, safe, efficacious and affordable health products and technologies in Kenya



Editorial Board

Editorial Advisor

Dr. Anthony Toroitch

Editor

Judy Sirima

Contributors

Judy Sirima

Naomi Naanyu

About The Newsletter

The PPB Newsletter is a publication of the Corporate Communication Division. It is designed to act as a tool of communication, documenting and disseminating important news and information to staff and stakeholders of the Board

Contacts

Corporate Communication Division,
Pharmacy and Poisons Board,
Lenana Road
P.O. Box 27663-00506 Nairobi.
Tel: +254-709-770-100
Email: pr@ppb.go.ke
info@ppb.go.ke
Web: web.pharmacyboardkenya.org

Design and Layout

Commwide Concepts

Email: commwideconcepts@gmail.com

Editor's Note

Service and progress

Welcome to the 31st Edition of the **Pharmacy and Poisons Board Newsletter**.

This issue highlights PPB's continued efforts to strengthen medicines regulation through collaboration, capacity building, and innovation.

From regional partnerships and GMP training to advancing Kenya's progress toward **WHO Maturity Level 3**, these milestones reflect our shared commitment to ensuring access to safe, quality, and effective health products for all.

UPCOMING EVENTS

- **Scientific Conference on Medical Products Regulation in Africa**



PHARMACY AND POISONS BOARD

pr@ppb.go.ke
info@ppb.go.ke



Pharmacy and Poisons Board



@ppbkenya

CONTENTS

- 5 Kenya Advances Toward WHO Maturity Level 3 in Regulatory Systems.**
- 6 East Africa Rallies Against Illicit Medicines as PPB Leads Regional Call for Cooperation.**
- 7 PPB and KPA Strengthen Partnership to Advance Pharmaceutical Practice in Kenya.**
- 8 PPB and Somali Medicines Authority Deepen Regional Cooperation.**
- 9 PPB Engages AIM Vaccine Co. Ltd on Strengthening Local Vaccine Manufacturing.**
- 10 PPB Showcases Leadership in Medicines Safety at Devolution Conference 2025.**
- 10 PPB Hosts Malawian AMR Committee to Strengthen Regional Cooperation.**
- 11 PPB Engages Pharmaceutical Stakeholders on Market Authorization and Public Safety.**
- 12 PPB and KRA Sign Agreement to Streamline Sea Cargo Clearance and Boost Trade Efficiency.**
- 13 PPB Hosts RAPSK Delegation to Strengthen Ethical and Regulatory Standards.**
- 13 PPB Hosts Moroccan Delegation to Explore Regional Healthcare Collaboration.**
- 14 PPB and PATH Conduct GMP Training to Boost Pharmaceutical Manufacturing Standards.**
- 15 PPB Explores Deeper Pharmaceutical Collaboration with India.**

Kenya Advances Toward WHO Maturity Level 3 in Regulatory Systems



The World Health Organization team pose for a photo with the Pharmacy and Poisons Board senior management

Kenya has taken a significant step forward in strengthening its regulatory framework, moving closer to achieving Maturity Level 3 (ML3) under the World Health Organization (WHO) Global Benchmarking Tool — a milestone that signals robust, reliable systems for regulating medicines and health products.



Pharmacy and Poisons Board Chairman, Dr. John Munyu, Chief Executive Officer, Dr. F. M. Siyoi and senior management officials during a meeting with the WHO team



Dr. Razieh Ostad Ali Dehaghi and Dr. Joseph Kabatende during a meeting at Pharmacy and Poisons Board

From 23rd to 26th September 2025, the Pharmacy and Poisons Board (PPB) hosted a five-day WHO mission led by Dr. Razieh Ostad Ali Dehaghi, alongside experts Joseph Kabatende, Helena Baiao, Rania Ibrahim Hassan, Engy Elhosary, and Edwin Ogara. The mission included

an Institutional Development Plan (IDP) follow-up and a Good Clinical Practice (GCP) Coached Audit.

The visit reviewed progress on previous recommendations and outlined next steps toward re-benchmarking of PPB and the National Quality Control Laboratory (NQCL).

The opening session was graced by PPB Board Chair, Dr. John Munyu, CEO, Dr. Fred Siyoi, Dr. Sultani Matendechero (Ag. CEO, NQCL), PPB directors, and senior management.

Attaining ML3 will position Kenya among countries recognized by WHO for having a mature, well-functioning regulatory system that ensures public access to safe, effective, and quality-assured health products.



Dr. Razieh Ostad Ali Dehaghi during a visit to the Pharmacy and Poisons Board Quality Control Laboratory

East Africa Rallies Against Illicit Medicines as PPB Leads Regional Call for Cooperation



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi makes his remarks during the Operation African Star 2 workshop

The Pharmacy and Poisons Board (PPB) has renewed its call for regional unity in the fight against illicit health products and technologies, underscoring the urgent need for stronger collaboration among East African regulators.

Speaking on July 10, 2025, during the opening of the Operation African Star 2 Workshop in Nairobi, PPB CEO, Dr. Fred Siyoi, warned that counterfeit, diverted, and illegally imported medicines are threatening public health, undermining economies, and eroding trust in health systems.

"The illicit trade in health products is a transnational crisis that thrives on weak coordination," said Dr. Siyoi. "It endangers lives and cannot be tackled in isolation. We must move as one."



Mr. Matthew Nice during the workshop

Building on the success of Operation African Star 1 in June 2024, which intercepted falsified medicines smuggled through courier networks, Dr. Siyoi credited improved intelligence sharing and joint enforcement across East Africa for disrupting illegal supply chains.

He highlighted Kenya's

Pharmaceutical Authentication and Traceability Program (PATP) as a game changer, enabling regulators to track medicines from production to patient, detect counterfeits in real time, and act swiftly on enforcement and recalls.

"Operation African Star 2 reaffirms our shared commitment to protecting the public and ensuring access to safe, quality-assured medicines," Dr. Siyoi noted. "We are embracing digitization, including AI-powered tools, to strengthen track-and-trace systems and safeguard the region's pharmaceutical supply chain."

The workshop brought together key partners, including Uganda's National Drug Authority, USAID-OIG, NABP, INCB, GS1, and Novartis, among others, to design practical, cross-border strategies for securing the regional supply chain.



Participants follow proceedings during the workshop



Operation Star 2 workshop participants pose for a group photo

Dr. Siyoi urged all regulators and partners to deepen collaboration through joint field operations, shared data systems, and harmonized regulatory frameworks to combat illicit trade more effectively.

"Let us protect lives, restore trust, and take decisive action in the fight against counterfeit medicines," he concluded.

PPB and KPA Strengthen Partnership to Advance Pharmaceutical Practice in Kenya



Pharmacy and Poisons Board Chairman Dr. John Munyu and Chief Executive Officer Dr. F. M. Siyoi during the meeting

that safeguard patients and support professional growth.

“The Board remains dedicated to upholding the highest regulatory standards to ensure patient safety and quality service delivery,” said Dr. Munyu. “We urge all practitioners to maintain compliance and uphold ethical conduct in line with professional standards.”

He emphasized the importance of partnerships between regulatory bodies and professional associations in positioning Kenya’s pharmaceutical industry for regional and global recognition.

The Pharmacy and Poisons Board (PPB) and the Kenya Pharmaceutical Association (KPA) have reaffirmed their shared commitment to advancing the standards and practice of pharmacy in Kenya.

On September 29, 2025, PPB Chairman, Dr. John Munyu, hosted KPA President, Mr. Chitechi Amboka, and members of the new National Executive Council (NEC) for a high-level engagement focused on collaboration, compliance, and professional excellence in the pharmaceutical sector.

Dr. Munyu commended KPA for its proactive leadership and reiterated PPB’s commitment to strengthening regulatory systems



Kenya Pharmaceutical Association President, Mr. Chitechi Amboka and Secretary General Mr. Eric Gichane during a meeting at Pharmacy and Poisons Board Headquarters



Pharmacy and Poisons Board Chairman, Dr. John Munyu makes his remarks during the meeting



Pharmacy and Poisons Director of Pharmacy Practice and Training, Dr. Wilfred Ochieng and Deputy Director, Dr. Dominic Mutie during the meeting

The meeting was also attended by PPB Chief Executive Officer, Dr. Fred Siyoi, and senior Board officials, marking a renewed phase of structured engagement between PPB and KPA to foster continuous improvement in pharmaceutical practice.



PPB and Somali Medicines Authority Deepen Regional Cooperation



Dr. Farah Sharawe and Dr. Anthony Toroitich engage during the meeting



Pharmacy and Poisons Board Director, Corporate Services, Dr. Anthony Toroitich chairs a meeting with the Somali delegates

The Pharmacy and Poisons Board (PPB) hosted a delegation from the Somali Medicines Regulatory Authority (SMRA) on September 8, 2025, to strengthen collaboration in medicines regulation and capacity development.

Discussions focused on key regulatory areas, including product listing, licensing, import control, market surveillance, and capacity building. The meeting highlighted the growing importance of cross-border cooperation in safeguarding the quality, safety, and efficacy of medicines across the Horn of Africa.

The Somali delegation was received by Dr. Anthony Toroitich, Director of Corporate Services, on behalf of PPB CEO, Dr. Fred Siyoi.



Pharmacy and Poisons Board Head of Legal Services, Mr. Kibet Kisorio makes his remarks during the meeting

“Regional collaboration is critical to strengthening regulatory systems and ensuring access to safe, quality-assured medicines,” said Dr. Toroitich.

The SMRA delegation comprised Farah Sharawe (Director, Interim NMRA Somalia), Mukhtar Shube (Director of Public Health, Federal Ministry of Health), Anisa Hassan, Abdullahi Omar, Shafie Ali, and Farhan Bashir (WHO Somalia Country Office).

PPB continues to provide technical assistance and knowledge exchange to regional counterparts, reinforcing Kenya’s leadership role in advancing regulatory excellence within the East and Horn of Africa.



The Somali delegates during the meeting



PPB Engages AIM Vaccine Co. Ltd on Strengthening Local Vaccine Manufacturing



AIM Vaccine delegates during a meeting at Pharmacy and Poisons Board

are committed to facilitating compliance with all regulatory requirements,” said Dr. Toroitich.

AIM Vaccine Co. Ltd expressed strong interest in establishing a vaccine manufacturing facility in Kenya — a move that aligns with national efforts to build resilience and self-sufficiency in vaccine production.

The engagement marks another milestone in Kenya’s journey toward advancing its pharmaceutical manufacturing capacity and enhancing health security.



Pharmacy and Poisons Board, Director of Corporate Services Dr. Anthony Toroitich during the meeting

International. The team was received by Dr. Anthony Toroitich, Director of Corporate Services, on behalf of PPB CEO, Dr. F. M. Siyoi.

Discussions focused on Kenya’s regulatory framework for vaccine production, including Good Manufacturing Practices (GMP), Marketing Authorization, Post-Marketing Surveillance, and Pharmacovigilance.

“PPB fully supports initiatives that strengthen local production of quality-assured vaccines. We



Pharmacy and Poisons Board Deputy Director of Inspectorate and Enforcement Dr. Dominic Kariuki

The Pharmacy and Poisons Board (PPB) hosted a high-level delegation from AIM Vaccine Co. Ltd on August 8, 2025, in discussions aimed at supporting Kenya’s goal to expand local vaccine manufacturing capacity.

The delegation, led by Mr. Yan Zhou, Chief Executive Officer of AIM Vaccine Co. Ltd, was accompanied by representatives from Livelite



PPB Showcases Leadership in Medicines Safety at Devolution Conference 2025



Pharmacy and Poisons Board Director of Pharmacy Practice and Training, Dr. Wilfred Ochieng pose for a photo with the PPB staff at the Devolution Conference

The Pharmacy and Poisons Board (PPB) took center stage at the Devolution Conference 2025, held from August 12–15, 2025, in Homa Bay County, where it showcased Kenya's progress in strengthening medicines regulation and promoting patient safety.



The PPB exhibition booth attracted delegates, professionals, partners, and members of the public eager to learn more about the Board's mandate and its role in protecting



Visitors at the Pharmacy and Poisons Board Booth



Dr. Lily Kipkeno engages a visitor at the Pharmacy and Poisons Board booth at the Devolution conference in Homa Bay County

public health.

Through live demonstrations, PPB staff highlighted the use of verification tools, shared insights on market surveillance initiatives, and outlined how robust regulatory oversight prevents the circulation of substandard and falsified medical products.

"Participation in this year's conference allowed us to strengthen partnerships and promote greater understanding of PPB's contribution to public health," noted a PPB representative.

Engagements with delegates reaffirmed the importance of collaboration and trust in building a strong, transparent regulatory system that safeguards the health and wellbeing of all Kenyans.

PPB Hosts Malawian AMR Committee to Strengthen Regional Cooperation

On August 21, 2025, the Pharmacy and Poisons Board (PPB) hosted a delegation from the Malawian Antimicrobial Resistance (AMR) Coordinating Committee, alongside representatives from the Kenya National Public Health Institute (KNPHI) and the East, Central and Southern Africa Health

Community (ECSA-HC).

The visit, led by Dr. Emmanuel Tanui from KNPHI, focused on Kenya's Surveillance System for Antimicrobial Consumption (KESAC) — a model initiative supporting evidence-based strategies to tackle antimicrobial resistance.



The Malawian AMR Committee during a meeting at Pharmacy and Poisons Board Headquarters



Pharmacy and Poisons Board Chief Principal Regulatory Officer, Dr. Ali Arale chairs a meeting with the Malawian AMR Committee



Hosting the delegation on behalf of PPB CEO, Dr. F. M. Siyoi, Dr. Ali Arale, Chief Principal Regulatory Officer, highlighted the importance of monitoring antimicrobial use as a cornerstone of effective AMR containment.

"Combating AMR requires strong regional cooperation, shared learning, and a coordinated

multi-sectoral approach," said Dr. Arale.

The engagement provided a platform for cross-country learning and reaffirmed the region's shared commitment to safeguarding public health through responsible antimicrobial use and stronger regulatory collaboration.

PPB Engages Pharmaceutical Stakeholders on Market Authorization and Public Safety



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi makes his remarks during the stakeholders meeting at PPB Headquarters

On August 12, 2025, the Pharmacy and Poisons Board (PPB) held a high-level consultative meeting with pharmaceutical industry stakeholders to deliberate on key issues surrounding Market Authorization of medical products in Kenya.



A section of the stakeholders and PPB staff during the meeting

The meeting, chaired by PPB Chief Executive Officer, Dr. F. M. Siyoi, brought together representatives from the Kenya Association of Pharmaceutical Industry (KAPI), Kenya Pharmaceutical Distributors Association (KPPDA), Medical Technology Industry Association of Kenya (MEDAK), Federation of Kenya Pharmaceutical Manufacturers (FKPM), and the Regulatory Affairs Professionals Society of Kenya (RAPSK).

Dr. Siyoi emphasized PPB's unwavering commitment to

stringent regulation and public safety, urging continuous collaboration between the regulator and industry players.

"Effective regulation requires partnership, transparency, and shared responsibility. Together, we can ensure all medical products in Kenya meet the highest standards of safety,



efficacy, and quality,” said Dr. Siyoi.

The forum underscored PPB’s proactive engagement with stakeholders to streamline processes, strengthen compliance, and enhance the safety of medical products available to the public.



PPB and KRA Sign Agreement to Streamline Sea Cargo Clearance and Boost Trade Efficiency



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi during the a meeting with KRA

The Pharmacy and Poisons Board (PPB) and the Kenya Revenue Authority (KRA) have signed a Service Level Agreement (SLA) to streamline the clearance of sea cargo, marking a significant step in improving trade facilitation and regulatory efficiency.

The agreement, signed on July 23, 2025, by PPB Chief Executive Officer, Dr. F. M. Siyoi, and KRA Assistant Manager, Customs and Border Control, Ms. Winfred Kinyua, follows a two-year collaboration involving 24 Partner Government Agencies (PGAs).

The SLA establishes clear roles, timelines, and joint processes among agencies to enhance accountability, coordination, and operational efficiency at Kenya’s ports. It aligns with the National



Kenya Revenue Authority Asst. Manager, Customs and Border Control, Ms. Winfred Kinyua, during the agreement signing

Trade Facilitation Agenda and the World Trade Organization (WTO) Trade Facilitation Agreement, reflecting Kenya’s commitment to transparent, predictable, and efficient trade systems.

“This agreement enhances our capacity to ensure that only safe, quality, and efficacious health products enter the country,” said Dr. Siyoi. “It is a milestone in strengthening inter-agency collaboration for better service delivery and public health protection.”


The partnership underscores PPB’s role in balancing public health safety with trade facilitation, ensuring that regulatory oversight keeps pace with Kenya’s growing import and export environment.



PPB Hosts RAPSK Delegation to Strengthen Ethical and Regulatory Standards



Pharmacy and Poisons Board Director of Health Products and Technologies Dr. Ahmed Mohamed makes his remarks during a meeting with the RAPSK team



The Pharmacy and Poisons Board (PPB) on July 22, 2025, hosted a delegation from the Regulatory Affairs Professional Society of Kenya (RAPSK) led by its Chairman, Dr. John Mwangi, for a courtesy visit focused on collaboration and ethical governance in the pharmaceutical sector.



Regulatory Affairs Professional Society of Kenya Chairman, Dr. John Mwangi during a meeting at the Pharmacy and Poisons Board



Pharmacy and Poisons Board Senior Officials, Dr. Ali Arale, Dr. Dominic Kariuki and Dr. Christabel Khaemba during the meeting

The meeting provided an opportunity to deliberate on policy and regulatory matters affecting the profession, with both institutions emphasizing the need for stronger partnerships to uphold

ethical standards and reinforce national regulatory systems.

The delegation was received by Dr. Ahmed Mohamed, Director of Health Products and Technologies, on behalf of the Chief Executive Officer, Dr. F. M. Siyoi.

"PPB values collaboration with professional associations like RAPSK as key partners in strengthening ethical practice and regulatory compliance," said Dr. Mohamed.



PPB Hosts Moroccan Delegation to Explore Regional Healthcare Collaboration

The Pharmacy and Poisons Board (PPB) on July 31, 2025, hosted a delegation from the Moroccan healthcare sector seeking to understand Kenya's regulatory framework for health products and technologies and explore opportunities for collaboration.

The visit provided a platform

for dialogue on regulatory alignment, knowledge exchange, and potential partnerships to strengthen healthcare systems across the region.

The Moroccan delegation comprised representatives from pharmaceutical and medical device manufacturers, distributors, and



An engagement session with the delegates at Pharmacy and Poisons Board



Pharmacy and Poisons Board Chief Principal Regulatory Officer, Dr. Ali Arale chairs a meeting with the Moroccan delegates

hospitals, who expressed interest in benchmarking Kenya's regulatory best practices and exploring investment opportunities in the health sector.



The team was received by Dr. Ali Arale, Chief Principal Regulatory Officer for Product Evaluation and Registration, on behalf of PPB Chief



The delegates pose for a photo with the PPB staff after the meeting

Executive Officer, Dr. F. M. Siyoi.

"This engagement reinforces Kenya's growing reputation as a regional leader in regulatory science and health system innovation," noted Dr. Arale.

The exchange highlighted PPB's commitment to fostering South-South cooperation and advancing partnerships that promote access to safe, effective, and quality health products across Africa.

PPB and PATH Conduct GMP Training to Boost Pharmaceutical Manufacturing Standards



Pharmacy and Poisons Board Director of Corporate Services, Dr. Anthony Toroitich makes his remarks during the workshop

On July 4, 2025, the Pharmacy and Poisons Board (PPB), in partnership with PATH, conducted a Good Manufacturing Practices (GMP) training session for local pharmaceutical manufacturers as part of its continuous efforts to enhance regulatory compliance

and quality assurance.

The training supports Kenya's progress toward achieving World Health Organization (WHO) Maturity Level 3, a major milestone in regulatory capacity building.

The session was officiated by Dr.

Anthony Toroitich, Director of Corporate Services, representing PPB CEO, Dr. F. M. Siyoi. He emphasized the importance of addressing gaps identified during GMP inspections and fostering



Pharmacy and Poisons Board Chief Principal Officer, Dr. Cheworei Csichei address the workshop participants



A section of the Local Pharmaceutical Manufacturer follow proceedings during the workshop

a robust, competitive local manufacturing sector.

"Our goal is to ensure that all locally produced health products meet the highest standards of quality, safety, and efficacy," said Dr. Toroitich. "Through training and collaboration, PPB is building a strong foundation for a self-reliant pharmaceutical industry."

The initiative underscores PPB's commitment to continuous



capacity building, industry support, and strategic partnerships that promote public health and pharmaceutical excellence.

PPB Explores Deeper Pharmaceutical Collaboration with India



Pharmacy and Poisons Board Director of Health Products and Technologies Dr. Ahmed Mohamed during the meeting with the Indian High Commissioner Mr. Sushil Prasad

The Pharmacy and Poisons Board (PPB) on July 1, 2025, held a high-level bilateral meeting with the Indian High Commissioner to Kenya, Mr. Sushil Prasad, and the Head of Commerce, Mr. Rishabh Kumar Rewal, to explore opportunities for enhanced pharmaceutical cooperation between Kenya and India.

Chaired by Dr. Ahmed Mohamed, Director of Health Products and Technologies, on behalf of PPB CEO, Dr. F. M. Siyoi, the meeting focused on regulatory capacity building, technical collaboration,



The Indian High Commissioner Sushil Prasad and the Head of Commerce Mr. Rishabh Kumar Rewal during a meeting at the Pharmacy and Poisons Board

and knowledge exchange in the pharmaceutical sector.

Key areas of discussion included:

- Capacity building in product registration, vaccine lot release, and inspectorate operations;
- Technology transfer to support local vaccine manufacturing; and
- The potential for mutual agreements with India's



Central Drugs Standard Control Organization and the Indian Pharmacopoeia.

"Kenya values India's global leadership in pharmaceuticals and looks forward to deepening collaboration that enhances regulatory excellence and supports local production," said Dr. Mohamed.

The engagement reaffirmed Kenya's commitment to fostering bilateral partnerships that promote innovation, sustainability, and access to safe, quality-assured medical products.





REPUBLIC OF KENYA

**MINISTRY OF HEALTH
PHARMACY AND POISONS BOARD**

**SAFETY ALERT FOR THE MEMBERS OF THE PUBLIC ON THE OFF-LABEL
USE OF SEMAGLUTIDE-CONTAINING COMPOUNDS FOR WEIGHT LOSS**

The Pharmacy and Poisons Board (PPB) is the National Medicines Regulatory Authority established under the Pharmacy and Poisons Act, Cap 244, Laws of Kenya (hereinafter "**the Act**"). The Board's core mandate is to ensure the quality, safety and efficacy of Health Products and Technologies (HPTs) in the country.

The Board wishes to bring to the attention of the public that **Semaglutide is a Prescription-Only Medicine** and its unsupervised or off-label use may result in serious health outcomes.

Semaglutide, commonly known to the public as **Ozempic and other generic** names, is approved for the treatment of adults with type 2 diabetes mellitus that is insufficiently controlled. While the benefits of Semaglutide outweigh its risks, serious safety concerns continue to be raised, particularly when it is used outside its approved medical purposes. Some of the most common side effects of Semaglutide include low blood sugar (hypoglycemia), eye conditions, acid (gastroesophageal) reflux disease, and intestinal obstruction, which can range from mild to severe.

In light of the foregoing safety concerns, the public is advised against the off-label use of the medicines and encouraged to report any suspected side effects and poor quality products through the following official reporting channels of the Pharmacy and Poisons Board (PPB);

- Pharmacovigilance Electronic Reporting System **pv.pharmacyboardkenya.org**
- Email: **pv@ppb.go.ke**
- Phone No: **+254 795 743 049**
- USSD Code (For the Public): ***271#**

The Board appreciates your continued support and collaboration in promoting the safe use of medicines.


Dr. F. M. Siyoi
CHIEF EXECUTIVE OFFICER

19th August, 2025



MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

PUBLIC ALERT

**SUBSTANDARD BATCHES OF PARACETAMOL 1000MG/100ML INJECTION
(LUMIDOL, PARAGEN, AND BLINK INJECTION)**

The Pharmacy and Poisons Board (hereinafter “the Board”) is the National Regulatory Authority under the Ministry of Health, established under the Pharmacy and Poisons Act Cap 244, Laws of Kenya (hereinafter “the Act”) mandated to protect and promote the health of the public by regulating the profession of pharmacy and ensuring access to quality, safe and efficacious health products and technologies.

In execution of the foregoing mandate, the Board draws public attention to the detection of substandard batches of Paracetamol 1000mg/100ml Injection identified in the Kenyan market, which have exhibited a color change.

1. **Lumidol Injection:** Batch Numbers **CM4594007**, **CM4594008**, and **CM4594009**, Manufactured by KamlaAmrut Pharmaceutical LLP, India.
2. **Blink Injection:** Batch Numbers **CS4594005** and **CS4594004** Manufactured by KamlaAmrut Pharmaceutical LLP, India.
3. **Paragen injection:** Batch Number **K4290027**, Manufactured by KamlaAmrut Pharmaceutical LLP, India.

In view of the above, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to **IMMEDIATELY CEASE** further distribution, sale, issuing, or use of the outlined product batches and return the same to their nearest healthcare facility or respective suppliers

The Board encourages the public to report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels:

- Online <https://pv.pharmacyboardkenya.org/users/mpublic>
- USSD code at *271#
- Mobile application: mPvERS both Android & iOS
- Email pv@ppb.go.ke or pms@ppb.go.ke
- Telephone No. 0795743049

The Board is committed to ensuring the safety and efficacy of medicines in the market to protect public health.


Dr. F. M. Siyoi
CHIEF EXECUTIVE OFFICER

24TH April 2025



PHARMACY AND POISONS BOARD

PUBLIC ALERT

MANDATED RECALL OF S-PRAZO (ESOMEPRAZOLE 40MG) BATCH NUMBER SPZ404 MANUFACTURED BY MEDICO REMEDIES PHARMACEUTICAL INDIA LIMITED

The Pharmacy and Poisons Board (hereinafter “the Board”) is the National Regulatory Authority under the Ministry of Health, established under the Pharmacy and Poisons Act Cap 244, Laws of Kenya (hereinafter “the Act”) mandated to protect and promote the health of the public by regulating the profession of pharmacy and ensuring access to quality, safe and efficacious health products and technologies.

In execution of the foregoing mandate, the Board draws public attention to the detection of product mix-up involving **S-Prazo (Esomeprazole 40mg) Batch No. SPZ404** wherein it was reported and confirmed that a strip of **Levofloxacin 500mg tablet** was found in a pack of Esomeprazole 40mg capsules.

In view of the above, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to **IMMEDIATELY CEASE** further distribution, sale, issuing, or use of the outlined product batch and return the same to their nearest healthcare facility or respective suppliers.

The Board encourages the public to promptly report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels:

- <https://pv.pharmacyboardkenya.org/users/mpublic>
- USSD code at *271#
- Mobile application: mPvERS both Android & iOS
- Email pms@ppb.go.ke or pv@ppb.go.ke
- Telephone No. 0795743049

The Board assures the public of its commitment to protecting public health.


Dr. F. M. Siyoi
CHIEF EXECUTIVE OFFICER

24th April 2025



PHARMACY AND POISONS BOARD

STOP ANTIMICROBIAL RESISTANCE!

You can help prevent AMR by:



- ✓ Using antibiotics only when prescribed
- ✓ Completing your full treatment
- ✓ Never sharing or using leftover antibiotics
- ✓ Practicing good hygiene & vaccination to prevent infections
- ✓ Avoiding self-medication & over-the-counter antimicrobials
- ✓ Disposing of antimicrobials safely

**YOUR ACTIONS TODAY PROTECT
FUTURE GENERATIONS!**



REPUBLIC OF KENYA

Pharmacy and Poisons Board



YOU DON'T HAVE TO BE CERTAIN, **JUST SUSPICIOUS!!!**

Report the following to PPB using the forms available online:

- Suspected poor quality medical products
- Suspected side effects following use of medicines, vaccines, medical devices, blood and blood products
- Medication errors

You Can report through the channels below:

PUBLIC/PATIENTS	
Website	pv.pharmacyboardkenya.org/padrs/add
Phone	+254 795 743 049 or report to the nearest health facility

HEALTH WORKERS	
Website	pv.pharmacyboardkenya.org/
Email	pv@pharmacyboardkenya.org
Phone	+254 795 743 049

